Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
SXS
Just bought back in at 3375.3p after the fall on their full year results. They may have further to fall now that sentiment for them has fallen somewhat but the second half of 2024 should see them back on track.
I dialled into the post statement call from Andrew Heath and Derik Harding.
All looks good here. Sales growth is slowing as the order intake returns towards "normal" after the pandemic. Margins, though, are up and they are happy to say that they will be in the top half of the forecast operating profits (£250m to £265m) for the current year. I have raised my eps figure for this year to just under 200p and was pleased to hear that cash conversion continues strong (? +110%). The two were rather confident about 2024 and made it clear that the inclusion of the words "Looking further ahead to 2024, we expect another year of progress, including further margin expansion" was deliberate.
Nothing to worry about here; with Book to Bill at 0.97 they are already producing for FY2024. The question is what rating will the market put on a share like this. They have fallen consistently for three months but with a prospective p/e nearing single figures and prospective yield nearing 3% they look good value to me. The share buy-back will be completed by this year end so support from this source ends then but they have been putting money into small bolt on acquisitions which hopefully add more value that buy-backs.
A good update - so why hasn't the sp fallen like many other shares?!
Well a welcome little change since yesterday!
Have held this for a long time now and still about 15% down. Another 5 years might see me break even!
Good company but one the market doesn't seem interested in.
pretty positive article
https://www.telegraph.co.uk/investing/shares/investors-think-much-cash-bad-thing-stocks-biggest-strength/
Rights issue can't be helping.
Seems like a pretty sound trading update to me. Recognises supply chain issues holding them back but otherwise firing on all cylinders. Any thoughts ?
(Not mine by the the way :) ) Earnings call on the way too......
Nov 26, 2015 at 05:00 Spectris profit down as weak trading persists Profit at precision instrument maker Spectris (SXS) is not measuring up, according to Deutsche Bank. Analyst Liz Bebb retained her ‘hold’ recommendation but reduced her target price to £18.30. The shares rose 20p to £17.21 yesterday. ‘Weaker trading conditions after the first half and resulting lower drop-through to the bottom line is not offset by cost reduction measures,’ she said. ‘We therefore reduce our earnings per share expectations for full-year 2015 and 2016 by 11-12%. We expect H2 2015 weakness to persist and have reduced segment profit expectations by 9% to £179 million, in line with management guidance. ‘For full-year 2016 estimates, organic growth is expected to be 1% to 1.5%, slightly below the level needed to offset underlying cost inflation; however, benefits from the cost restructuring program undertaken in H2 2015 are expected to offset the remaining inflation, leading to broadly flat margins year-on-year.’
23 November 2015 3:33am Numis analysts have reiterated a “hold” position for Spectris, due to a more difficult than expected second half, with underlying revenue down around 1.5 per cent year-on-year for 2015. Performance in China has held up, contrary to fears and there has been some positive momentum for new product launches. The target price has been lifted to 1,835p from 1,704p.
High volume. Any reason?
Instrumentation and controls developer Spectris has acquired US-based ReliaSoft for approximately £28m in cash. The FTSE 250 group said the deal for the American firm, a provider of engineering software and consultancy, will be funded from existing cash and bank facilities. The Arizona-based firm will be integrated with HBM nCode within Spectris' test and measurement division, the group added in a statement on Friday
SXS SPECTRIS, lovely technical set up, see chart below. https://pbs.twimg.com/media/B1rboOdCcAAeiIq.jpg"
IMS today IMHV
Spectris plc 2013 Trading Update notification - 17 January 2014 10 January 2014 - Spectris plc (SXS: LSE), the productivity-enhancing instrumentation and controls company, will announce its 2013 full year trading update on Friday 17 January 2014 at 07:00 BST. John O'Higgins, Chief Executive and Clive Watson, Group Finance Director, will host an investor and analyst conference call at 08:00 GMT.
"The difficult market conditions in the second half of 2012 provided a backdrop for Spectris to demonstrate the quality and resilience of its business model," Michael Blogg, an analyst at Investec, commented this morning. "We have revised our estimates from a basis of ultra-caution to a level achievable in a low-growth environment, with upside potential if markets recover more quickly. The increase in our target price, driven by the 6-7% increase in our earnings per share (EPS) estimates, is not quite enough to justify a more positive recommendation than hold." He added: "Spectris has the spread and market presence to deliver growth in most circumstances, augmented by its organic and bolt-on investments financed out of cash flows and overseen by a highly-respected management team. "It is now within striking distance of the FTSE 100, where we believe it would not look out of place in terms of investment quality.
Spectris: N+1 Singer takes target price from 2135p to 2415p, while reiterating a hold recommendation.
"The board is confident that Spectris continues to be strategically well-positioned for 2013 and beyond." The group said it expects to see growth in its Life Sciences sector continue, but said its Mining sector looks set to continue to slow in the first half of 2013. "We also see potential in the emerging nano-materials sector, creating demand from academic research institutions, as well as in-house research and development laboratories in the pharmaceutical and advanced materials sectors," it said. Sales in Test & Measurement rose 3.0% on a like-for-like basis, while operating profit grew 0.7%, helped by strong demand from the electronics and telecoms markets and continued growth in automotive. In-line Instrumentation sales climbed 4.0%, and operating profit rose 0.5%, after it experienced good demand from Asia Pacific, Japan and China in particular.
Productivity-enhancing instrumentation company Spectris posted an 11 per cent rise in annual sales for 2012, contributing to the same percentage rise in adjusted earnings per share. Sales for the 12 months climbed from 1,106.2m to 1,230.8m year-on-year, while adjusted profit before tax increased to 217.3m from 191.6m, resulting in adjusted earnings per share of 137.5p (2011: 124.1p). Actual pre-tax profit totalled 186.7m, compared to 166m the previous year. The dividend was increased by 16% from 33.6p to 39.0p per share. John O'Higgins, Chief Executive, said: "This strong result was achieved through the progress we made on all aspects of our strategy. We will continue to invest in new products and applications which enhance our customers' productivity, seek further geographic growth opportunities across the group, and improve the resilience of the business through organic and acquisition activities.
Spectris: Investec raises target price from 2345p to 2400p and downgrades to hold.
The sale was completed after the close of business on January 31st.
Productivity-enhancing instrumentation company Spectris has completed the sale of its Fusion UV business to Heraeus Holding GmbH for a total cash consideration of 172m dollars, the post-tax proceeds of which will be used to pay down debt. The sale is expected to be somewhat dilutive to earnings per share in 2013 and the impact on earnings per share is expected to be approximately five pence. Fusion UV is a provider of industrial ultraviolet curing systems and technology worldwide. The company's core competency is in the area of microwave powered, electrode-less lamp technology to generate intense UV energy that is used for UV curing.
You beauty !!!!